Targeting the ERK signaling pathway in cancer therapy

Annals of Medicine

Volumn 38, Issue 3, 2006, Pages 200-211

  Kohno, Michiaki ^a   Pouyssegur, Jacques ^b  

^a NAGASAKI UNIVERSITY   (Japan)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

Author keywords

Anticancer drug; Cancer; Combination therapy; ERK pathway; MEK inhibitor; Molecular targeted therapy; Raf inhibitor

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ANTINEOPLASTIC AGENT; ARRY 142886; BZA 2B; CETUXIMAB; CISPLATIN; CYTARABINE; CYTOSTATIC AGENT; CYTOTOXIC AGENT; DOCETAXEL; ERLOTINIB; FTI 2148; GEFITINIB; LAPATINIB; LONAFARNIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; PACLITAXEL; PROTEIN INHIBITOR; RAF PROTEIN; SORAFENIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE;

ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CELL DIFFERENTIATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; RASH; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MAP KINASE SIGNALING SYSTEM; RAF KINASES; UP-REGULATION;

EID: 33646399160     PISSN: 07853890     EISSN: 16512219     Source Type: Journal    
DOI: 10.1080/07853890600551037     Document Type: Review

References (73)

1. mapk are required for fibroblast proliferation. Proc Natl Acad Sci. 1993;90:8319-23.
2. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J. 1995;9:726-35.
3. Lewis TS, Shapiro PS, Ahn NG. Signal transduction through MAP kinase cascades. Adv Cancer Res. 1998;74:49-139.
4. Pouyssegur J, Lenormand P. Fidelity and Spatio-temporal control in MAP kinase (ERKs) signaling. Eur J Biochem. 2003;270:3291-9.
5. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene. 1999;18:813-22.
6. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res. 1999;59:279-84.
7. Oka H, Chatani Y, Hoshino R, Ogawa O, Kakehi Y, Terachi T, et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res. 1995;55:4182-7.
8. English JM, Cobb MH. Pharmacological inhibitors of MAPK pathway. Trend Pharmacol Sci. 2002;23:40-5.
9. Kohno M, Pouyssegur J. Pharmacological inhibitors of the ERK signaling pathway: application as an anticancer drugs. Prog Cell Cycle Res. 2003;5:219-24.
10. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nature Rev Cancer. 2004;4:937-47.
11. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist. 2002;7:31-9.
12. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to Gefitinib therapy. Science. 2004;304:1497-500.
13. Cox AD, Der CJ. Ras family signaling: therapeutic targeting. Cancer Biol Ther. 2002;1:599-606.
14. Downward J. Targeting RAS signaling pathways in cancer therapy. Nature Rev. Cancer. 2003;3:11-2.
15. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-54.
16. Wan PTC, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116:855-67.
17. Theodosiou A, Ashworth A. MAP kinase phosphatases. Genome Biol. 2002;3:Reviews 3009.
18. Kim HJ, Bar-Sagi D. Modulation of signaling by Sprouty: a developing story. Nature Rev Mol Cell Biol. 2004;5:441-50.
19. Kwabi-Addo B, Wang J, Erdem H, Vaid A, Castro P, Ayala G, et al. The expression of sproutyl, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Res. 2004;64:4728-35.
20. Lo TL, Yusoff P, Fong CW, Guo K, McCaw BJ, Phillips WA, et al. The Ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sproutyl and Sprouty2 are deregulated in breast cancer. Cancer Res. 2004;64:6127-36.
21. Manzano RG, Montuenga LM, Dayton M, Dent P, Kinoshita I, Vicent S, et al. CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential. Oncogene. 2002;21:4435-47.
22. Cobb MH, Goldsmith EJ. How MAP kinases are regulated. J Biol Chem. 1995;270:14843-6.
23. Herbst RS, Fukuoka M, Baselga J. Gefitinib - a novel targeted approach to treating cancer. Nature Rev Cancer. 2004;4:956-65.
24. Sebti SM, Der CJ. Searching for the elusive targets of farnesyltransferase inhibitors. Nature Rev Cancer. 2003;3:945-51.
25. Zhu K, Hamilton AD, Sebti SM. Farnesyltransferase inhibitors as anticancer agents: current status. Curr Opin Investig Drugs. 2003;4:1428-35.
26. Lackner MR, Kindt RM, Carroll PM, Brown K, Cancilla MR, Chen C, et al. Chemical genetics identifies Rab geranylgeranyl transferase as an apoptotic target of farnesyl transferase inhibitors. Cancer Cell. 2005;7:325-36.
27. Kip1. J Biol Chem. 2001;276:2686-92.
28. Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. Cell. 1996;84:359-69.
29. Tanimura S, Chatani Y, Hoshino R, Sato M, Watanabe S, Kataoka T, et al. Activation of the 41/43·kDa mitogen-activated protein kinase signaling pathway is required for hepatocyte growth factor-induced cell scattering. Oncogene. 1998;17:57-65.
30. Tanimura S, Nomura K, Ozaki K, Tsujimoto M, Kondo T, Kohno M. Prolonged nuclear retention of activated extracellular signal-regulated kinase 1/2 is required for hepatocyte growth factor-induced cell motility. J Biol Chem. 2002;277:28256-64.
31. Reddy KB, Nabha SM, Atanaskova N. Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev. 2003;22:395-403.
32. Welch DR, Sakamaki T, Pioquinto R, Leonard TO, Goldberg SF, Hon Q, et al. Transfection of Constitutively Active Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase Confers Tumorigenic and Metastatic Potentials to NIH3T3 Cells. Cancer Res. 2000;60:1552-6.
33. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA. Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol. 1997;137:481-92.
34. Semenza GL. Targeting HIF-α for cancer therapy. Nature Rev Cancer. 2003;3:721-32.
35. Pages G, Pouyssegur J. Transcriptional regulation of the Vascular Endothelial Growth Factor gene - a concert of activating factors. Cardiovasc Res. 2005;65:564-73.
36. Richard DE, Berra E, Gothie E, Roux D, Pouyssegur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1α (HIF-1α) and enhance the transcriptional activity of HIF-1. J Biol Chem. 1999;274:2631-7.
37. Brahimi-Horn C, Mazure N, Pouyssegur J. Signalling via the hypoxia-inducible factor 1α requires multiple posttranslational modifications. Cell Signal. 2005;17:1-9.
38. Eliceiri BP, Klemke R, Stromblad S, Cheresh. , DA. Integrin αvβ3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol. 1998;140:1255-63.
39. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaera K, Wiland A, Gowan RC, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Med. 1999;5:810-6.
40. Tanimura S, Asato K, Fujishro S, Kohno M. Specific blockade of the ERK pathway inhibits the invasiveness of tumor cells: down-regulation of matrix metalloproteinase-3/-9/-14 and CD44. Biochem Biophys Res Commun. 2003;304:801-6.
41. Kimura ET, Nikiforova NM, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454-7.
42. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418:934.
43. Wan PTC, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116:855-67.
44. V599EB-RAF is an oncogene in melanocytes. Cancer Res. 2004;64:2338-42.
45. V599E in human melanoma abrogates transformation. Cancer Res. 2003;63:5198-202.
46. Lyons JF, Wilhelm S, Hibner B, Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer. 2001;8:219-25.
47. Wilhelm SM, Carter C, Tang LY, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-109.
48. Clark JW, Eder JP, Ryan D, Lathia C, Lenz H-J. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res. 2005;11:5472-80.
49. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2005;23:965-72.
50. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel. , AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA. 1995;92:7686-9.
51. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, et al. Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase. J Biol Chem. 1998;273:18623-32.
52. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000;351:95-105.
53. Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nature Struct Mol Biol. 2004;11:1192-7.
54. LoRusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol. 2005;23:5281-93.
55. Rinehart J, Adjei AA, LoRusso PM, Waterhouse D, Hecht JR, Natale RB, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol. 2004;22:4456-62.
56. Menon SS, Whitfield LR, Sadis S, Meyer MB, Leopold J, Lorusso PM, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of PD 0325901, a second generation MEK inhibitor after multiple oral doses of PD 0325901 to advanced cancer patients. Proc Am Soc Clin Oncol. 2005;23:3066.
57. Lyssikatos J, Yeh T, Wallace E, Marsh V, Bernat B, Gross S, et al. ARRY-14886, a potent and selective MEK inhibitor: I) ATP-independent inhibition results in high enzymatic and cellular selectivity. Proc Am Assoc Cancer Res. 2004;45:3888.
58. Yeh T, Walace E, Lyssikatos J, Winkler J. ARRY-14886, a potent and selective MEK inhibitor: II) Potency against cellular MEK leads to inhibition of cellular proliferation and induction of apoptosis in cell lines with mutant Ras or B-Raf. Proc Am Assoc Cancer Res. 2004;45:3889.
59. Lee P, Wallace E, Yeh T, Poch G, Litwiler K, Pheneger T, et al. ARRY-14886, a potent and selective MEK inhibitor: III) Efficacy against human xenograft models correlates with decreased ERK phosphorylation. Proc Am Assoc Cancer Res. 2004;45:3890.
60. Dent P, Grant S. Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: Potential role in promoting cytotoxic drug action. Clin Cancer Res. 2001;7:775-83.
61. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 1995;270:1326-31.
62. MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem. 1996;271:20608-16.
63. Deng X, Ruvolo P, Carr B, May WS Jr. Survival function of ERK1/2 as IL-3-activated, staurosporine-resistant Bcl2 kinases. Proc Nad Acad Sci USA. 2000;97:1578-83.
64. Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, et al. Inhibition of Bcl-2 associated death agonist (BAD) phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res. 2000;60:5988-94.
65. Persons DL, Yazlovitskaya EM, Pelling JC. Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem. 2000;275:35778-85.
66. Townsend KJ, Trusty JL, Traupman MA, Eastman A, Craig RW. Expression of the antiapoptotic MCL1 gene product is regulated by a mitogen activated protein kinase-mediated pathway triggered through microtubule disruption and protein kinase C. Oncogene. 1998;17:1223-34.
67. McDaid HM, Lopez-Barcons L, Grossman A, Lia M, Keller S, Román Pérez-Soler R, et al. Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res. 2005;65:2854-60.
68. Watanabe K, Noda S, Iwashita K, Tanimura S, Ozaki K, Kohno M. Blockade of the extracellular signal-regulated kinase pathway enhances the anti-tumor activity of microtubule depolymerizing agents in tumor cells in which the pathway is constitutively activated. Proc Am Assoc Cancer Res. 2002;43:2891.
69. Ozaki K, Minoda A, Kishikawa F, Kohno M. Blockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitor-induced cell death. Biochem Biophys Res Commun. 2006;339:1171-7.
70. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nature Rev Cancer. 2002; 2, 489-501.
71. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 2002;14:381-95.
72. Guo W, Giancotti FG. Integrin signaling during tumour progression. Nature Rev Mol Cell Biol. 2004;5:816-26.
73. Schlaepfer DD, Mitra SK. Multiple connections link FAK to cell motility and invasion. Curr Opin Genet Dev. 2004;14:92-101.